Silexion Therapeutics Corp. (SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, will execute a 1-for-15 reverse share split of its ordinary shares, effective after market close on July 28, 2025.
Trading on a split-adjusted basis will begin July 29 under the same ticker, with a new CUSIP assigned. Every fifteen ordinary shares will be consolidated into one, with the par value rising from $0.0009 to $0.0135 per share.
CEO Ilan Hadar said the reverse split reflects the company's commitment to retaining its Nasdaq listing and building a strong growth foundation. He expressed confidence in advancing Silexion's RNAi therapeutics, following recent preclinical successes and an expanded development strategy for KRAS-driven cancers. The split is also intended to improve capital markets positioning, reduce share price volatility, and further progress toward delivering transformative treatments for hard-to-treat cancers.
SLXN currently trades at $7.23 or 4.24% lower on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.